{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_references_citation in Reference Text / Citation (approximate match)
Status:
Other
Class:
POLYMER
Status:
US Previously Marketed
Source:
21 CFR 310.545(a)(20) weight control maltodextrin
Source URL:
First approved in 1984
Source:
NeuroBion by BENARD INDUSTRIES INC
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 346
(2012)
Source URL:
First approved in 2012
Source:
21 CFR 346
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
Novipet by Novipet, Inc.
(2012)
Source URL:
First approved in 2012
Source:
Novipet by Novipet, Inc.
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
THERAFLEX Glucosamine Plus Max by Bayer Healthcare Llc.
Source URL:
First approved in 2012
Source:
21 CFR 347
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2010)
Source URL:
First approved in 2010
Source:
21 CFR 348
Source URL:
Class:
POLYMER
Status:
Investigational
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04353518: Phase 3 Interventional Unknown status COVID-19
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04387760: Phase 2 Interventional Completed SARS-CoV 2
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03554109: Phase 2 Interventional Withdrawn Triple Negative Breast Cancer (TNBC)
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
